What is Zacks Small Cap’s Estimate for ACHV FY2025 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Analysts at Zacks Small Cap cut their FY2025 earnings estimates for shares of Achieve Life Sciences in a research report issued on Monday, November 10th. Zacks Small Cap analyst J. Vandermosten now anticipates that the biopharmaceutical company will post earnings per share of ($1.23) for the year, down from their prior estimate of ($1.15). The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. Zacks Small Cap also issued estimates for Achieve Life Sciences’ Q4 2025 earnings at ($0.24) EPS.

Achieve Life Sciences (NASDAQ:ACHV) last posted its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.04).

Several other research firms have also commented on ACHV. Weiss Ratings reiterated a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Tuesday. HC Wainwright assumed coverage on Achieve Life Sciences in a research note on Thursday, August 21st. They issued a “buy” rating and a $12.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Achieve Life Sciences Stock Down 1.0%

ACHV stock opened at $4.72 on Wednesday. Achieve Life Sciences has a 52 week low of $1.84 and a 52 week high of $5.78. The company has a quick ratio of 6.64, a current ratio of 6.64 and a debt-to-equity ratio of 0.21. The firm has a 50-day simple moving average of $3.75 and a 200-day simple moving average of $3.17. The stock has a market capitalization of $241.22 million, a P/E ratio of -3.23 and a beta of 1.62.

Insider Buying and Selling at Achieve Life Sciences

In other news, CMO Cindy Jacobs sold 27,629 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $2.77, for a total value of $76,532.33. Following the completion of the sale, the chief marketing officer directly owned 115,585 shares in the company, valued at $320,170.45. This represents a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Mark K. Oki sold 50,060 shares of the stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $2.92, for a total value of $146,175.20. Following the completion of the sale, the chief financial officer directly owned 127,940 shares of the company’s stock, valued at approximately $373,584.80. This represents a 28.12% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 381,972 shares of company stock worth $1,084,997. 3.00% of the stock is owned by company insiders.

Institutional Trading of Achieve Life Sciences

Several institutional investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. increased its stake in Achieve Life Sciences by 81.3% during the 2nd quarter. Franklin Resources Inc. now owns 4,459,014 shares of the biopharmaceutical company’s stock worth $10,077,000 after buying an additional 2,000,079 shares during the period. Hudson Bay Capital Management LP acquired a new stake in shares of Achieve Life Sciences during the second quarter worth about $2,652,000. Simplify Asset Management Inc. increased its position in Achieve Life Sciences by 443.7% during the second quarter. Simplify Asset Management Inc. now owns 1,184,512 shares of the biopharmaceutical company’s stock worth $2,677,000 after buying an additional 966,667 shares during the period. Stonepine Capital Management LLC acquired a new position in shares of Achieve Life Sciences in the 2nd quarter valued at $753,000. Finally, Vanguard Group Inc. raised its holdings in shares of Achieve Life Sciences by 14.5% in the third quarter. Vanguard Group Inc. now owns 2,461,802 shares of the biopharmaceutical company’s stock valued at $7,755,000 after buying an additional 311,925 shares during the last quarter. Institutional investors and hedge funds own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.